A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

Trial Profile

A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Hydroxychloroquine (Primary) ; Sorafenib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by VG Life Sciences media release.
    • 04 Sep 2014 Status changed from recruiting to active, no longer recruiting, as reported in a VG Life Sciences media release.
    • 04 Sep 2014 Interim results added from the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top